More than 60 leading researchers said Pfizer’s clinical trial shouldn’t be rushed as it needed to monitor participants for at least two months after they received the second dose.
More than 60 leading researchers said Pfizer’s clinical trial shouldn’t be rushed as it needed to monitor participants for at least two months after they received the second dose.